AgeX Therapeutics Inc (AGE) USD0.0001
AgeX Therapeutics Inc. is a biotechnology company. The Company is focused on the development and commercialization of therapeutics targeting human aging. Its induced Tissue Regeneration (iTR) technology is based telomerase-mediated cellular immortality and regenerative biology. Its pipeline includes two cell-based, two drug-based therapeutic products, online database products and research products. The Company’s AGEX-BAT1 is its cell therapy product candidate that is being developed for the treatment of certain age-related metabolic disorders, such as Type II (adult-onset) diabetes. AGEX-VASC1 is its cell-based therapy that is designed to restore vascular support in aged ischemic tissues such as the aging heart. AGEX-iTR1547 is its drug-based formulation developed to restore regenerative potential in an array of aged tissues afflicted with degenerative disease using its proprietary iTR technology. Renelon is its iTR product candidate designed to promote scar less tissue repair.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.